PPIDT00230
Drug Information
| Name | Belatacept |
|---|---|
| Sequence | MHVAQPAVVLASSRGIASFVCEYASPGKYTEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYEGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB06681 |
| Type | biotech |
| Indication | For prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Solution | Parenteral |
250.00 mg
|
| Injection, powder, for solution | Intravenous |
250 MG
|
| Injection, powder, lyophilized, for solution | Intravenous |
250 mg/1
|
| Injection, powder, lyophilized, for solution | Intravenous |
25000000 mg
|